Global digital metered dose inhaler market to reach $4.9 billion by 2026

  • Global competitiveness and percentage market shares of main competitors
  • Market presence in multiple geographies – Strong/Active/Niche/Trivial
  • Peer-to-peer collaborative online interactive updates
  • Access to our digital archives and the MarketGlass research platform
  • Free updates for one year

Editing: 5; Published: February 2022
Executive commitments: 576
Companies: 23 – Players covered include 3M Company; AptarGroup, Inc.; AstraZeneca Plc; Cipla Inc.; GlaxoSmithKline plc. ; Glenmark Pharmaceuticals; H&T Presspart Manufacturing Ltd. ; Koninklijke Philips NV; Novartis International SA; Opko Health, Inc.; Philips Respironics; Propeller health; Sensirion SA Switzerland; Teva Pharmaceutical Industries Ltd. and others.
Cover: All major geographies and key segments
segments: Product (measured dose, dry powder); Type (brand, generic); Application (asthma, COPD, other applications)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; UK; Spain; Russia; and rest of Europe); Asia Pacific (Australia; India; South Korea; and rest of Asia Pacific); Latin America (Argentina; Brazil; Mexico; and rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and rest of Middle East); and Africa.

Free Project Preview – This is an ongoing global program. Preview our research program before making a purchasing decision. We provide free access to qualified executives in strategy, business development, sales and marketing, and product management roles at featured companies. Insights provide insider access to business trends; competing brands; profiles of experts in the field; and market data models and much more. You can also create your own bespoke report using our MarketGlass™ platform which offers thousands of bytes of data with no obligation to purchase our report. Registry overview

ABSTRACT-

Global digital metered dose inhaler market to reach $4.9 billion by 2026
Digital metered dose inhalers are advanced smart devices intended to treat and manage the delivery of medication for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Digital metered dose inhalers deliver a precise amount of medication into the patient’s lungs in the form of a short burst of aerosol medication. Patients can self-administer these drugs by inhalation. These devices have built-in sensors to record inhaler usage and measure inspiratory flow in accordance with dose management. The growth of the global market is poised to benefit from the rising prevalence of various respiratory disorders, favorable reimbursement policies, and technological advancements. The digital metered dose inhaler market is propelled by increasing cases of chronic respiratory diseases including asthma, respiratory allergies, chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea which negatively affect the quality life of patients. COPD accounts for approximately 6% or more than 3 million deaths worldwide, with low- to middle-income countries reporting more than 90% of these deaths, creating a significant demand for advanced respiratory devices. The market is further driven by the growing aging population which is highly vulnerable to mild to severe forms of respiratory disorders. These next-generation devices are also benefiting from the growing adoption of digital devices, the pressing requirement for patient compliance with medications, the need for dose tracking, and significant investment in R&D activity. to offer miniaturized and innovative devices.

Amid COVID-19 crisis, Global Digital Metered Dose Inhalers Market Estimated at US$3.1 billion in 2022, is expected to reach a revised size of US$4.9 billion by 2026, growing at a CAGR of 13.1% over the analysis period. Metered Dose, one of the segments analyzed in the report, is expected to grow at a CAGR of 12.4% to reach US$3.4 billion at the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the dry powders segment is readjusted to a revised CAGR of 14.3% for the next 7-year period. This segment currently accounts for a 35.7% share of the global digital metered-dose inhaler market. The metered dose segment is dominating the market due to its wide availability, rising incidence of chronic heart disease and increasing healthcare expenditure. These inhalers present a user-friendly and cost-effective option for users that ensures accurate delivery of the dose to be inhaled. Metered-dose inhalers are taking advantage of the rise in cases of respiratory conditions, including chronic respiratory disorders, chronic obstructive pulmonary disease, and asthma. The segment is benefiting from a growing awareness of the many advantages of advanced devices over conventional options. The metered dose inhaler segment is poised to be bolstered by the growing use of soft mist inhalers owing to the growing adoption of improved drug delivery systems coupled with ongoing technological advancements. On the other hand, the dry powder inhaler segment is expected to witness the fastest growth rate over the next few years owing to the increasing concerns associated with drug irritation caused by the propellant components present in metered dose inhalers, such as chlorofluorocarbons.

The US market is estimated at $1.3 billion in 2022, when China is expected to reach $418.2 million by 2026
The digital metered dose inhaler market in the United States is estimated at US$1.3 million in 2022. The country currently accounts for a 42.48% share of the global market. Chinaworld’s second largest economy, is expected to reach an estimated market size of US$418.2 million in 2026 with a CAGR of 16.4% over the analysis period. Other notable geographic markets include Japan and Canada, each predicting growth of 11% and 11.7% respectively over the analysis period. In Europe, Germany is expected to grow at around 12.6% CAGR while the rest of the European market (as defined in the study) will reach US$480.1 million at the end of the analysis period.

An interesting trend to note is ongoing trials targeting the use of inhalers to treat COVID-19. Researchers have developed a life-saving inhaler-based treatment that has the potential to protect patients with COVID-19 from severe signs. The approach is based on a protein, interferon beta-1a (SNG001), which is produced by the body during a viral infection. Inhaling the protein should trigger the immune response and prompt the cells to fight the virus. In another development, a group of researchers isolated an antibody from llamas with the potential to treat or prevent COVID-19. The antibody would be administered to patients using inhalers. After

MarketGlass™ Platform
Our MarketGlass™ platform is a free comprehensive knowledge center that can be custom configured to meet the intelligence needs of today’s busy business executives! This interactive, influencer-focused research platform is at the heart of our core research engagements and draws on the unique perspectives of participating executives from around the world. Features include – enterprise-wide peer-to-peer collaborations; overviews of research programs relevant to your business; 3.4 million profiles of experts in the field; profiles of competitive companies; interactive research modules; custom report generation; follow market trends; competing brands; create and publish blogs and podcasts using our primary and secondary content; follow domain events around the world; and much more. Client companies will have privileged access to the project’s data stacks. Currently used by over 67,000 domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our mobile application which has just been released on iOS or android

About Global Industry Analysts, Inc. and StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher, the only influencer-focused market research company in the world. Proudly serving over 42,000 clients in 36 countries, GIA has been recognized for its accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
E-mail: [email protected]

CONNECTIONS
Join our group of experts
https://www.strategyr.com/Panelist.asp

Connect with us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow us on twitter
https://twitter.com/marketbytes

Journalists and media
[email protected]

SOURCE Global Industry Analysts, Inc.